Click here to close now.

Welcome!

Web 2.0 Authors: Carmen Gonzalez, Ian Khan, Elizabeth White, Dana Gardner, Plutora Blog

News Feed Item

Global Pharmaceutical Survey 2013-2014 - Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry

NEW YORK, Feb. 20, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Pharmaceutical Survey 2013-2014 - Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry

http://www.reportlinker.com/p0795163/Global-Pharmaceutical-Survey-2013-2014---Market-Trends-Marketing-Spend-and-Sales-Strategies-in-the-Global-Pharmaceutical-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Product Synopsis
"Global Pharmaceutical Survey 2013-2014: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry" is a new report by ICD Research that analyzes how pharmaceutical industry companies' media spend, marketing and sales strategies and practices, and business planning are set to change in 2013-2014. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable). This report provides the current size of the marketing and advertising budgets of global pharmaceutical industry suppliers and how spending by global pharmaceutical industry suppliers will change, providing an insight into global marketing behaviour. In addition, the report identifies future growth of global pharmaceutical industry buyers and suppliers and MandA activity. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by region, company type and sizes."

Introduction and Landscape
Why was the report written?
This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading global pharmaceutical industry executives. The report provides data and analysis on global pharmaceutical industry suppliers' media spend, marketing and sales strategies, and practices and business planning within the global pharmaceutical industry. This report includes key topics such as media channel spending outlooks, media budgets, marketing agency selection criteria, business challenges, and sales tactics of leading suppliers within the global pharmaceutical industry. The report also identifies global pharmaceutical industry buyers' and suppliers' future growth, MandA and investment expectations. Most secondary research reports are based on general industry drivers and do not understand the industry executives' attitude and changing behaviours, creating a gap in presenting the business outlook of the industry. In an effort to bridge this gap, ICD Research created this primary-research based report by gathering the opinions of multiple stake holders in the value-chain of the global pharmaceutical industry

What is the current market landscape and what is changing?
The average size of the annual marketing budget of global pharmaceutical industry supplier respondents stood at US$4.2 million in 2012, a figure that decreased to US$2.6 million in 2013.

What are the key drivers behind recent market changes?
In the process of choosing marketing agencies, the 'ability to target specific audience niches', 'strategic and tactical consulting', and the 'ability to generate leads or setup customer meetings' are considered the most important factors by global pharmaceutical industry suppliers.

What makes this report unique and essential to read?
This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading pharmaceutical industry companies. This report provides the reader with a definitive analysis of the industry outlook and explores how opportunities and demand are set to change in 2013-2014. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable). Furthermore, the report reveals the current size of pharmaceutical industry suppliers' marketing and advertising budgets and how expenditure by industry suppliers will change, providing insight into global marketing behavior. This report identifies the key marketing aims of organizations and the sales strategies companies will adopt in order to adapt to market conditions in 2013. Additionally, this chapter also aims to identify key amendments to marketing agencies that aid business generation, respondents' criteria for marketing agency selection, and attitudes towards marketing and sales.

Key Features and Benefits
Projects industry trends and revenue growth expectations in 2013.

Drive revenues by understanding future product investment areas and key growth regions.

Uncover key challenges and opportunities and identify key actions required to maintain and win buyer business.

Formulate effective sales and marketing strategies by identifying the overall size of the marketing budgets of global pharmaceutical industry supplier companies.

Identifies the key marketing aims of organizations and which sales strategies companies will be adopting to deal with market conditions in 2013-2014.

Key Market Issues
China, Brazil, and India are the important emerging markets to offer growth in 2013.

'Market uncertainty', 'responding to price pressure', 'rising competition', and 'regulatory changes' are the leading business concerns for the global pharmaceutical industry in 2013.

The average size of the annual marketing budget of global pharmaceutical industry supplier respondents stood at US$4.2 million in 2012, a figure that decreased to US$2.6 million in 2013.

'Social media and networking sites', 'email and newsletters', and 'conferences and events' are expected to have increased expenditure in 2013 as identified by 56%, 48%, and 44% of respondents respectively.

Overall, 'competitor and market intelligence research', 'customer intelligence and analytics', and 'business performance management solutions' were identified as the marketing and sales solutions most expected to be invested in during 2013.

Key Highlights
An analysis of revenue growth expectations by senior level respondents reveals that 62% are 'more optimistic' about their company's revenue growth in 2013.

A significant percentage of pharmaceutical manufacturing industry respondents highlighted that capital expenditure towards 'new product development', 'employee training', and 'IT infrastructure development' would increase in 2013.

The top three priorities for global pharmaceutical industry buyer respondents in 2013 are 'new products and services', 'improve operational efficiency', and 'expand in current markets'.

A total of 49% of respondents from pharmaceutical manufacturing companies, 68% of respondents from CRO and CMO companies, and 64% of respondents from pharmaceutical industry supplier companies anticipate an increase in their current workforce in 2013.

Survey results show that respondents from the global pharmaceutical industry identified the US as offering the highest growth potential among developed countries in 2013-2014.

Table of Contents

1 Introduction
1.1 What is This Report About?
1.2 Definitions
1.3 Methodology
1.4 Profile of Survey Respondents: Global Pharmaceutical Industry
1.4.1 Global pharmaceutical industry: profile of buyer respondents
1.4.2 Global pharmaceutical industry: profile of supplier respondents
2 Executive Summary
3 Global Pharmaceutical Industry Dynamics
3.1 Revenue Growth Projections in the Global Pharmaceutical Industry
3.1.1 Revenue growth projections by company type
3.1.2 Revenue growth projections by region
3.1.3 Revenue growth projections by company turnover
3.1.4 Global pharmaceutical industry: revenue growth expectations by senior level respondents
3.2 Future Developments in Business Structure in the Global Pharmaceutical Industry
3.2.1 Future developments in business structure by buyers
3.2.2 Future developments in business structure by suppliers
3.2.3 Future developments in business structure by region
3.2.4 Future developments in business structure by company turnover
3.2.5 Future developments in business structure by senior level respondents
3.3 Change in Leading Company Strategies in the Global Pharmaceutical Industry
3.3.1 Change in leading company strategies by buyers
3.3.2 Change in leading company strategies by suppliers
3.3.3 Change in leading company strategies by region
3.3.4 Change in leading company strategies by company turnover
3.4 Merger and Acquisition (MandA) Activity Projections in the Global Pharmaceutical Industry
3.4.1 MandA activity projections by buyers
3.4.2 MandA activity projections by suppliers
3.4.3 MandA activity projections by region
3.4.4 MandA activity projections by company turnover
3.4.5 MandA activity projections by purchasing decision authority
3.4.6 Global pharmaceutical industry - expand abroad Vs MandA activity projections
3.5 Estimation of Capital Expenditure in the Global Pharmaceutical Industry
3.5.1 Estimation of capital expenditure by buyers
3.5.2 Estimation of capital expenditure by suppliers
3.5.3 Estimation of capital expenditure by region
3.5.4 Estimation of capital expenditure by company turnover
3.6 Planned Change in Staff Recruitment Activity in the Global Pharmaceutical Industry
3.6.1 Planned change in staff recruitment activity by buyers
3.6.2 Planned change in staff recruitment activity by suppliers
3.6.3 Planned change in staff recruitment activity by region
3.6.4 Planned change in staff recruitment activity by company turnover
4 Global Pharmaceutical Industry Market Growth Outlook
4.1 Global Pharmaceutical Industry: Demand in Emerging Markets
4.1.1 Demand in emerging markets by buyers
4.1.2 Demand in emerging markets by suppliers
4.1.3 Demand in emerging markets by region
4.1.4 Demand in emerging markets by company turnover
4.2 Global Pharmaceutical Industry - Growth Projections in Developed Countries
4.2.1 Growth projections in developed countries by buyers
4.2.2 Growth projections in developed countries by suppliers
4.2.3 Growth projections in developed countries by region
4.2.4 Growth projections in developed countries by company turnover
5 Threats and Opportunities for the Global Pharmaceutical Industry
5.1 Global Pharmaceutical Industry: Leading Business Concerns for 2013-2014
5.1.1 Leading business concerns for 2013-2014 by company type
5.1.2 Leading business concerns for 2013-2014 by region
5.1.3 Leading business concerns for 2013-2014 by company turnover
5.2 Global Pharmaceutical Industry: Key Supplier Actions to Maintain and Win Buyer Business
5.2.1 Actions to maintain and secure buyer business by buyers
5.2.2 Actions to maintain and secure buyer business by region
5.2.3 Actions to maintain and secure buyer business by company turnover
5.2.4 Actions to maintain and secure buyer business by purchasing decision authority
6 Global Pharmaceutical Industry - Supplier Marketing Spend Activity
6.1 Annual Marketing Budgets - Global Pharmaceutical Industry Suppliers
6.1.1 Annual marketing budgets by region - global pharmaceutical industry suppliers
6.1.2 Annual marketing budgets by company turnover - global pharmaceutical industry suppliers
6.2 Planned Change in Marketing Expenditure Levels - Global Pharmaceutical Industry Suppliers
6.2.1 Planned change in marketing expenditure by region - global pharmaceutical industry suppliers
6.2.2 Planned change in marketing expenditure by turnover - global pharmaceutical industry suppliers
6.2.3 Planned change in marketing expenditure by decision making authority - global pharmaceutical industry suppliers
6.2.4 Planned change in marketing expenditure levels vs. revenue growth expectations (%), 2013
6.3 Future Investment by Media Channel - Global Pharmaceutical Industry Suppliers
6.3.1 Future investment by media channel by region - global pharmaceutical industry suppliers
6.3.2 Future investment by media channel by company turnover - global pharmaceutical industry suppliers
6.4 Global Pharmaceutical Industry Suppliers' Future Investment in Marketing and Sales
6.4.1 Planned investment in marketing and sales technologies by region - global pharmaceutical industry suppliers
6.4.2 Planned investment in marketing and sales by turnover: global pharmaceutical industry suppliers
7 Marketing and Sales Behaviors and Strategies in 2013-2014
7.1 Key Marketing Aims for 2013-2014 - Global Pharmaceutical Industry Suppliers
7.1.1 Key marketing aims by region - global pharmaceutical industry suppliers
7.1.2 Key marketing aims by company turnover - global pharmaceutical industry suppliers
7.2 Essential Amendments to Marketing Activities in 2013-2014
7.2.1 Amendments to marketing activities by company turnover - global pharmaceutical industry suppliers
7.3 Critical Success Factors for Choosing a Marketing Agency
7.3.1 Critical success factors for choosing a marketing agency by region
7.3.2 Critical success factors by company turnover - global pharmaceutical industry suppliers
8 Appendix
8.1 Global Pharmaceutical Industry Survey Results- Closed Questions
8.2 Methodology
8.3 Contact us
8.4 About ICD Research
8.5 Disclaimer

List of Tables

Table 1: Global Pharmaceutical Industry Survey Respondents by Company Type, 2013
Table 2: Global Pharmaceutical Industry Buyer Respondents by Job Role (%), 2013
Table 3: Global Pharmaceutical Industry Buyer Respondents by Region (%), 2013
Table 4: Global Pharmaceutical Industry Buyer Respondents by Company Turnover (%), 2013
Table 5: Global Pharmaceutical Industry Supplier Respondents by Job Role (%), 2013
Table 6: Global Pharmaceutical Industry Supplier Respondents by Region (%), 2013
Table 7: Global Pharmaceutical Industry Supplier Respondents by Company Turnover (%), 2013
Table 8: Revenue Growth Optimism in the Global Pharmaceutical Industry (%), 2010-2013
Table 9: Revenue Growth Optimism in the Global Pharmaceutical Industry by Buyers (%), 2010-2013
Table 10: Revenue Growth Optimism in the Global Pharmaceutical Industry by Suppliers (%), 2010-2013
Table 11: Revenue Growth Optimism in the Global Pharmaceutical Industry by Region (%),2013
Table 12: Revenue Growth Optimism in the Global Pharmaceutical Industry by Turnover (%), 2013
Table 13: Revenue Growth Optimism by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Table 14: Key Expected Changes in Business Structure by Buyers - Global Pharmaceutical Industry (%), 2013
Table 15: Key Expected Changes in Business Structure by Suppliers - Global Pharmaceutical Industry (%), 2013
Table 16: Key Expected Changes in Business Structure by Turnover - Global Pharmaceutical Industry (%), 2013
Table 17: Key Expected Changes In Business Structure by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Table 18: Change in Leading Company Strategies by Buyers - Global Pharmaceutical Industry (%), 2013
Table 19: Change in Leading Company Strategies by Suppliers - Global Pharmaceutical Industry (%), 2013
Table 20: Change in Leading Company Strategies by Region - Global Pharmaceutical Industry (%), 2013
Table 21: MandA Activity Projections - Global Pharmaceutical Manufacturers' Industry (%), 2010-2013
Table 22: MandA Activity Projections - Global CROs and CMOs (%), 2010-2013
Table 23: MandA Activity Projections - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Table 24: Global Pharmaceutical Industry MandA Activity Projections by Region (%), 2013
Table 25: Global Pharmaceutical Industry MandA Activity Projections by Turnover (%), 2013
Table 26: Global Pharmaceutical Industry MandA Activity Projections by Purchasing Decision Authority (%), 2013
Table 27: Global Pharmaceutical Industry - Expand Abroad vs. MandA Activity Projections(%), 2013
Table 28: Change in Capital Expenditure by Global Pharmaceutical Industry Manufacturers(%), 2013
Table 29: Change in Capital Expenditure by Global CROs and CMOs (%), 2013
Table 30: Change in Capital Expenditure by Pharmaceutical Industry Suppliers (%), 2013
Table 31: Global Pharmaceutical Industry - Increase in Capital Expenditure by Region (%), 2013
Table 32: Global Pharmaceutical Industry Manufacturers - Planned Change in Staff Recruitment (%), 2013
Table 33: Global Pharmaceutical Industry Suppliers - Planned Change in Staff Recruitment Activity (%), 2013
Table 34: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Region (%), 2013
Table 35: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Turnover (%), 2013
Table 36: Global Pharmaceutical Industry Manufacturers - Demand in Emerging Markets (%), 2013
Table 37: Global Pharmaceutical Industry CROs and CMOs - Demand in Emerging Markets (%), 2013
Table 38: Global Pharmaceutical Industry Suppliers - Demand in Emerging Markets (%), 2013
Table 39: Global Pharmaceutical Manufacturers- Growth Projections in Developed Countries (%), 2013
Table 40: Global Pharmaceutical CROs and CMOs- Growth Projections in Developed Countries (%), 2013
Table 41: Global Pharmaceutical Industry Suppliers - Growth Projections in Developed Countries (%), 2013
Table 42: Global Pharmaceutical Industry - Increase in Growth Projections of Developed Countries by Turnover (%), 2013
Table 43: Global Pharmaceutical Industry - Leading Business Concerns (%), 2010-2013
Table 44: Global Pharmaceutical Industry - Leading Business Concerns by Company Type (%), 2013
Table 45: Global Pharmaceutical Industry - Leading Business Concerns by Region (%), 2013-2014
Table 46: Global Pharmaceutical Industry - Securing Buyer Business: Buyer vs. Supplier Responses (%), 2013
Table 47: Actions to Secure Buyer Business, Global Pharmaceutical Industry Buyer Responses (%), 2013
Table 48: Global Pharmaceutical Industry - Securing Buyer Business by Turnover (%), 2013
Table 49: Securing Buyer Business in the Global Pharmaceutical Industry - by Purchasing Decision Authority (%), 2013
Table 50: Annual Marketing Budgets - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Table 51: Annual Marketing Budgets by Region - Global Pharmaceutical Industry Suppliers (%), 2013
Table 52: Annual Marketing Budgets by Turnover - Global Pharmaceutical Industry Suppliers (%), 2013
Table 53: Planned Change in Marketing Expenditure - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Table 54: Planned Change in Marketing Expenditure Levels by Region (%), 2013
Table 55: Planned Change in Marketing Expenditure Levels by Company Turnover (%), 2013
Table 56: Planned Change in Marketing Expenditure Levels by Decision Making Authority (%), 2013
Table 57: Change in Marketing Expenditure Levels by Revenue Growth Expectations (%), 2013
Table 58: Future Investment by Media Channels - Global Pharmaceutical Industry Suppliers (%), 2013
Table 59: Planned Investment in Marketing and Sales Technologies - Global Pharmaceutical Industry Suppliers (%), 2013
Table 60: Key Marketing Aims - Global Pharmaceutical Industry Suppliers (%), 2013
Table 61: Amendments to Marketing Activities - Global Pharmaceutical Industry Suppliers (%), 2013
Table 62: Amendments to Marketing Activities by Company Turnover - Global Pharmaceutical Industry Suppliers (%), 2013
Table 63: Critical Success Factors - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Table 64: Survey Results - Closed Questions

List of Figures

Figure 1: Revenue Growth Optimism in the Global Pharmaceutical Industry (%), 2010-2013
Figure 2: Revenue Growth Optimism in the Global Pharmaceutical Industry by Company Type (%), 2010-2013
Figure 3: Revenue Growth Optimism in the Global Pharmaceutical Industry by Region (%), 2013
Figure 4: Revenue Growth Optimism in the Global Pharmaceutical Industry by Turnover (%), 2013
Figure 5: Revenue Growth Optimism by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Figure 6: Key Expected Changes in Business Structure by Buyers - Global Pharmaceutical Industry (%), 2013
Figure 7: Key Expected Changes in Business Structure by Suppliers - Global Pharmaceutical Industry (%), 2013
Figure 8: Key Expected Changes in Business Structure by Region - Global Pharmaceutical Industry (%), 2013
Figure 9: Change in Leading Company Strategies by Buyers - Global Pharmaceutical Industry (%), 2013
Figure 10: Change in Leading Company Strategies by Suppliers - Global Pharmaceutical Industry (%), 2013
Figure 11: Change in Leading Company Strategies by Region - Global Pharmaceutical Industry (%), 2013
Figure 12: Change in Leading Company Strategies by Turnover - Global Pharmaceutical Industry (%), 2013
Figure 13: MandA Activity Projections - Global Pharmaceutical Industry (%), 2013
Figure 14: MandA Activity Projections - Global Pharmaceutical Manufacturers' Industry (%), 2010-2013
Figure 15: MandA Activity Projections - Global CROs and CMOs (%), 2010-2013
Figure 16: MandA Activity Projections - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Figure 17: Global Pharmaceutical Industry MandA Activity Projections by Region (%), 2013
Figure 18: Global Pharmaceutical Industry MandA Activity Projections by Turnover (%), 2013
Figure 19: Global Pharmaceutical Industry MandA Activity Projections by Purchasing Decision Authority (%), 2013
Figure 20: Global Pharmaceutical Industry - Expand Abroad Vs MandA Activity Projections (%), 2013
Figure 21: Change in Capital Expenditure by Global Pharmaceutical Industry Manufacturers(%), 2013
Figure 22: Change in Capital Expenditure by Global CROs and CMOs (%), 2013
Figure 23: Change in Capital Expenditure by Pharmaceutical Industry Suppliers (%), 2013
Figure 24: Global Pharmaceutical Industry - Increase in Capital Expenditure by Turnover (%), 2013
Figure 25: Global Pharmaceutical Industry Manufacturers - Planned Change in Staff Recruitment (%), 2013
Figure 26: Global Pharmaceutical Industry Suppliers - Planned Change in Staff Recruitment Activity (%), 2013
Figure 27: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Region (%), 2013
Figure 28: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Turnover (%), 2013
Figure 29: Global Pharmaceutical Industry: Top Ten Growth Regions (%), 2013
Figure 30: Global Pharmaceutical Industry: Top Five Emerging Markets, 2013
Figure 31: Global Pharmaceutical Industry Manufacturers - Demand in Emerging Markets (%), 2013
Figure 32: Global Pharmaceutical Industry CROs and CMOs - Demand in Emerging Markets (%), 2013
Figure 33: Global Pharmaceutical Industry Suppliers - Demand in Emerging Markets (%), 2013
Figure 34: Global Pharmaceutical Industry - Demand in Emerging Markets by Region (%), 2013
Figure 35: Global Pharmaceutical Industry - Demand in Emerging Markets by Turnover (%), 2013
Figure 36: Global Pharmaceutical Industry - Top Five Developed Regions by Growth (%), 2013
Figure 37: Global Pharmaceutical Manufacturers- Growth Projections in Developed Countries (%), 2013
Figure 38: Global Pharmaceutical CROs and CMOs- Growth Projections in Developed Countries (%), 2013
Figure 39: Global Pharmaceutical Industry Suppliers - Growth Projections in Developed Countries (%), 2013
Figure 40: Global Pharmaceutical Industry - Increase in Growth Projections of Developed Countries by Region (%), 2013
Figure 41: Global Pharmaceutical Industry - Top Five Leading Business Concerns, 2013
Figure 42: Global Pharmaceutical Industry - Leading Business Concerns (%), 2013
Figure 43: Global Pharmaceutical Industry - Leading Business Concerns by Company Type (%), 2013
Figure 44: Global Pharmaceutical Industry - Leading Business Concerns by Turnover (%), 2013-2014
Figure 45: Global Pharmaceutical Industry - Securing Buyer Business: Buyer vs. Supplier Responses (%), 2013
Figure 46: Actions to Secure Buyer Business, Global Pharmaceutical Industry Buyer Responses (%), 2013
Figure 47: Global Pharmaceutical Industry - Securing Buyer Business by Region (%), 2013
Figure 48: Annual Marketing Budgets - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Figure 49: Annual Marketing Budgets by Region - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 50: Annual Marketing Budgets by Turnover - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 51: Planned Change in Marketing Expenditure - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Figure 52: Planned Change in Marketing Expenditure Levels by Region (%), 2013
Figure 53: Planned Change in Marketing Expenditure Levels by Decision Making Authority (%), 2013
Figure 54: Future Investment by Media Channels - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 55: Global Pharmaceutical Industry Suppliers - Investment in Media Channels by Region (%), 2013
Figure 56: Global Pharmaceutical Industry Suppliers - Investment in Media Channels by Turnover (%), 2013
Figure 57: Planned Investment in Marketing and Sales Technologies - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 58: Planned Investment in Marketing and Sales Technologies by Region - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 59: Planned Investment in Marketing and Sales Technologies by Company Turnover - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 60: Key Marketing Aims - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 61: Key Marketing Aims by Region - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 62: Key Marketing Aims by Turnover - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 63: Amendments to Marketing Activities - Global Pharmaceutical Industry Suppliers (%) , 2013
Figure 64: Amendments to Marketing by Turnover - Global Pharmaceutical Industry Suppliers (%) , 2013
Figure 65: Critical Success Factors - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 66: Critical Success Factors by Region - Global Pharmaceutical Industry Suppliers (%), 2013
Figure 67: Critical Success Factors by Turnover - Global Pharmaceutical Industry Suppliers (%), 2013

Companies Mentioned

Eli Lilly , Avid Radiopharmaceuticals , Roche , Johnson and Johnson , Mozambica , Mozambican Medicines Company , Mylan Pharmaceuticals Private Limited , AstraZeneca , MedImmune , WuXi AppTec , Pfizer , Bristol-Myers , Sanofi , Astellas Pharma , Sanwa Kagaku Kenkyusho , STS Health , Avita Medical , Guppy Plastics , Mylan Laboratories , TiGenix , DiaMedica , Suzhou Pharma , Arrowhead Research , Shire , biOasis Technologies , UCB , Immunovative Therapies , Lonza , UBICHEM Group , UBICHEM Pharma , BASF , Equateq , SAFC , Sigma-Aldrich , Semantelli , Novartis , UMN Pharma , Catalent Pharma Solutions , Sihuan Pharmaceutical Holdings , Dendreon Corporation , DBV Technologies , GENEWIZ , Bayer HealthCare Pharmaceuticals , Vitapath , Nextrials , LGC , Quotient Bioresearch , Bio-Rad Laboratories , AbD Serotec , MorphoSys AG , NextWave Pharmaceuticals , OPKO Health , DiscoveRx , BioSeek , Poxel , Nuron Biotech , Takeda, Takeda America Holdings, LigoCyte Pharmaceuticals, Block Engineering, Lexmark International, Acuo Technologies, Zhejiang Hisun Pharmaceuticals, Abbot, Essex Woodlands, Novavax, CPL Biologicals, Dr. Reddy's Laboratories, Debiopharm Group, Omkar Speciality Chemicals, Thermo Fisher Scientific, Bosch Packaging Technology, Amgen, TG Therapeutics, Ildong Pharmaceutical, Teva Pharmaceutical Industries, Handok Pharmaceuticals, Aptuit, Biophytis, Boehringer Ingelheim, Super Supplements, Mercent, Amazon, eBay, ANTS, TetraPak, Darbox and Visiopharm

To order this report:
Pharmaceutical Industry:
Global Pharmaceutical Survey 2013-2014 - Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
One of the biggest impacts of the Internet of Things is and will continue to be on data; specifically data volume, management and usage. Companies are scrambling to adapt to this new and unpredictable data reality with legacy infrastructure that cannot handle the speed and volume of data. In his session at @ThingsExpo, Don DeLoach, CEO and president of Infobright, will discuss how companies need to rethink their data infrastructure to participate in the IoT, including: Data storage: Understanding the kinds of data: structured, unstructured, big/small? Analytics: What kinds and how responsiv...
The Workspace-as-a-Service (WaaS) market will grow to $6.4B by 2018. In his session at 16th Cloud Expo, Seth Bostock, CEO of IndependenceIT, will begin by walking the audience through the evolution of Workspace as-a-Service, where it is now vs. where it going. To look beyond the desktop we must understand exactly what WaaS is, who the users are, and where it is going in the future. IT departments, ISVs and service providers must look to workflow and automation capabilities to adapt to growing demand and the rapidly changing workspace model.
Sensor-enabled things are becoming more commonplace, precursors to a larger and more complex framework that most consider the ultimate promise of the IoT: things connecting, interacting, sharing, storing, and over time perhaps learning and predicting based on habits, behaviors, location, preferences, purchases and more. In his session at @ThingsExpo, Tom Wesselman, Director of Communications Ecosystem Architecture at Plantronics, will examine the still nascent IoT as it is coalescing, including what it is today, what it might ultimately be, the role of wearable tech, and technology gaps stil...
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. He discussed opportunities and challenges ahead for the IoT from a market and technical point of vie...
Hadoop as a Service (as offered by handful of niche vendors now) is a cloud computing solution that makes medium and large-scale data processing accessible, easy, fast and inexpensive. In his session at Big Data Expo, Kumar Ramamurthy, Vice President and Chief Technologist, EIM & Big Data, at Virtusa, will discuss how this is achieved by eliminating the operational challenges of running Hadoop, so one can focus on business growth. The fragmented Hadoop distribution world and various PaaS solutions that provide a Hadoop flavor either make choices for customers very flexible in the name of opti...
The true value of the Internet of Things (IoT) lies not just in the data, but through the services that protect the data, perform the analysis and present findings in a usable way. With many IoT elements rooted in traditional IT components, Big Data and IoT isn’t just a play for enterprise. In fact, the IoT presents SMBs with the prospect of launching entirely new activities and exploring innovative areas. CompTIA research identifies several areas where IoT is expected to have the greatest impact.
Advanced Persistent Threats (APTs) are increasing at an unprecedented rate. The threat landscape of today is drastically different than just a few years ago. Attacks are much more organized and sophisticated. They are harder to detect and even harder to anticipate. In the foreseeable future it's going to get a whole lot harder. Everything you know today will change. Keeping up with this changing landscape is already a daunting task. Your organization needs to use the latest tools, methods and expertise to guard against those threats. But will that be enough? In the foreseeable future attacks w...
Disruptive macro trends in technology are impacting and dramatically changing the "art of the possible" relative to supply chain management practices through the innovative use of IoT, cloud, machine learning and Big Data to enable connected ecosystems of engagement. Enterprise informatics can now move beyond point solutions that merely monitor the past and implement integrated enterprise fabrics that enable end-to-end supply chain visibility to improve customer service delivery and optimize supplier management. Learn about enterprise architecture strategies for designing connected systems tha...
Wearable devices have come of age. The primary applications of wearables so far have been "the Quantified Self" or the tracking of one's fitness and health status. We propose the evolution of wearables into social and emotional communication devices. Our BE(tm) sensor uses light to visualize the skin conductance response. Our sensors are very inexpensive and can be massively distributed to audiences or groups of any size, in order to gauge reactions to performances, video, or any kind of presentation. In her session at @ThingsExpo, Jocelyn Scheirer, CEO & Founder of Bionolux, will discuss ho...
Even as cloud and managed services grow increasingly central to business strategy and performance, challenges remain. The biggest sticking point for companies seeking to capitalize on the cloud is data security. Keeping data safe is an issue in any computing environment, and it has been a focus since the earliest days of the cloud revolution. Understandably so: a lot can go wrong when you allow valuable information to live outside the firewall. Recent revelations about government snooping, along with a steady stream of well-publicized data breaches, only add to the uncertainty
SYS-CON Events announced today that Dyn, the worldwide leader in Internet Performance, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Dyn is a cloud-based Internet Performance company. Dyn helps companies monitor, control, and optimize online infrastructure for an exceptional end-user experience. Through a world-class network and unrivaled, objective intelligence into Internet conditions, Dyn ensures traffic gets delivered faster, safer, and more reliably than ever.
As organizations shift toward IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection &E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 16th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships, will discuss how to cut costs, scale easily, and unleash insight with CommVault Simpana software, the only si...
Cloud data governance was previously an avoided function when cloud deployments were relatively small. With the rapid adoption in public cloud – both rogue and sanctioned, it’s not uncommon to find regulated data dumped into public cloud and unprotected. This is why enterprises and cloud providers alike need to embrace a cloud data governance function and map policies, processes and technology controls accordingly. In her session at 15th Cloud Expo, Evelyn de Souza, Data Privacy and Compliance Strategy Leader at Cisco Systems, will focus on how to set up a cloud data governance program and s...
Roberto Medrano, Executive Vice President at SOA Software, had reached 30,000 page views on his home page - http://RobertoMedrano.SYS-CON.com/ - on the SYS-CON family of online magazines, which includes Cloud Computing Journal, Internet of Things Journal, Big Data Journal, and SOA World Magazine. He is a recognized executive in the information technology fields of SOA, internet security, governance, and compliance. He has extensive experience with both start-ups and large companies, having been involved at the beginning of four IT industries: EDA, Open Systems, Computer Security and now SOA.
The industrial software market has treated data with the mentality of “collect everything now, worry about how to use it later.” We now find ourselves buried in data, with the pervasive connectivity of the (Industrial) Internet of Things only piling on more numbers. There’s too much data and not enough information. In his session at @ThingsExpo, Bob Gates, Global Marketing Director, GE’s Intelligent Platforms business, to discuss how realizing the power of IoT, software developers are now focused on understanding how industrial data can create intelligence for industrial operations. Imagine ...
Operational Hadoop and the Lambda Architecture for Streaming Data Apache Hadoop is emerging as a distributed platform for handling large and fast incoming streams of data. Predictive maintenance, supply chain optimization, and Internet-of-Things analysis are examples where Hadoop provides the scalable storage, processing, and analytics platform to gain meaningful insights from granular data that is typically only valuable from a large-scale, aggregate view. One architecture useful for capturing and analyzing streaming data is the Lambda Architecture, representing a model of how to analyze rea...
SYS-CON Events announced today that Vitria Technology, Inc. will exhibit at SYS-CON’s @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Vitria will showcase the company’s new IoT Analytics Platform through live demonstrations at booth #330. Vitria’s IoT Analytics Platform, fully integrated and powered by an operational intelligence engine, enables customers to rapidly build and operationalize advanced analytics to deliver timely business outcomes for use cases across the industrial, enterprise, and consumer segments.
HP and Aruba Networks on Monday announced a definitive agreement for HP to acquire Aruba, a provider of next-generation network access solutions for the mobile enterprise, for $24.67 per share in cash. The equity value of the transaction is approximately $3.0 billion, and net of cash and debt approximately $2.7 billion. Both companies' boards of directors have approved the deal. "Enterprises are facing a mobile-first world and are looking for solutions that help them transition legacy investments to the new style of IT," said Meg Whitman, Chairman, President and Chief Executive Officer of HP...
Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 16th Cloud Expo at the Javits Center in New York June 9-11 will find fresh new content in a new track called PaaS | Containers & Microservices Containers are not being considered for the first time by the cloud community, but a current era of re-consideration has pushed them to the top of the cloud agenda. With the launch of Docker's initial release in March of 2013, interest was revved up several notches. Then late last...
The explosion of connected devices / sensors is creating an ever-expanding set of new and valuable data. In parallel the emerging capability of Big Data technologies to store, access, analyze, and react to this data is producing changes in business models under the umbrella of the Internet of Things (IoT). In particular within the Insurance industry, IoT appears positioned to enable deep changes by altering relationships between insurers, distributors, and the insured. In his session at @ThingsExpo, Michael Sick, a Senior Manager and Big Data Architect within Ernst and Young's Financial Servi...